Early colorectal cancer: diagnosis, treatment and survivorship care

Buccafusca, Gabriella; Proserpio, Ilaria; Tralongo, Antonino Carmelo; Giuliano, Sebastiano Rametta; Tralongo, Paolo

doi:10.1016/j.critrevonc.2019.01.023

Cited by 138 publications

(105 citation statements)

References 162 publications

Supporting

Mentioning

104

Contrasting

Unclassified

Order By: Relevance

“…However, a previous review [32] reported that the reliability of the self-reported time spent on TV watching was consistently moderate to high; r=0.69-0.83, p < 0.001. Third, residual confounding cannot be eliminated; for example, we do not have data on CRC screening or the time or the stage of cancer at diagnosis in our cohort study which are important factors associated with CRC mortality [20,33]. Last, although the age and BMI of the studied participants did not differ than those of the excluded ones; however, those excluded due to missing data on the TV viewing time carried more risky profile such as less walking activity, higher prevalence of smokers and alcohol drinkers which could infer some sort of unavoidable selection bias.…”

Section: Discussionmentioning

confidence: 99%

Television Viewing Time and the Risk of Colorectal Cancer Mortality among Japanese Population: The JACC Study

Eshak

Cui

et al. 2021

Cancer Res Treat

View full text Add to dashboard Cite

Sedentary behavior attributes to the increased risk of some cancers and all-cause mortality. The evidence is limited for the association between television (TV) viewing time, a major sedentary behavior, and risk of colorectal cancer death. We aimed to examine this association in Japanese population. Methods and Methods A prospective cohort study encompassed of 90,834 men and women aged 40-79 years with no prior history of colorectal cancer who completed a self-administered food frequency questionnaire, and provided their TV viewing information. The participants were followed-up from 1988-1990 to the end of 2009. The hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated by the Cox proportional hazard regression for risk of colorectal cancer mortality according to TV viewing time. Results: During the median 19.1-year follow-up period, we documented 749 (385 men and 364 women) colorectal cancer deaths. The multivariable-adjusted HRs for mortality from colorectal cancer were 1.

show abstract

Section: Discussionmentioning

confidence: 99%

Television Viewing Time and the Risk of Colorectal Cancer Mortality among Japanese Population: The JACC Study

Eshak

Cui

et al. 2021

Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…CRC is frequently diagnosed at an advanced stage, and distant metastases contribute to its high mortality rate [2]. It is a complex disease that involves interactions between genetic and environmental factors in the intestinal epithelium [3]. The normal epithelium accumulates changes over 20-40 years, progressing from different dysplasia grades to the establishment of local and distant metastasis [4,5].…”

Section: Introductionmentioning

confidence: 99%

Circulating let-7e-5p, miR-106a-5p, miR-28-3p, and miR-542-5p as a Promising microRNA Signature for the Detection of Colorectal Cancer

Silva

Barros-Filho

Wong

et al. 2021

Cancers

View full text Add to dashboard Cite

Colorectal cancer (CRC) is a disease with high incidence and mortality. Colonoscopy is a gold standard among tests used for CRC traceability. However, serious complications, such as colon perforation, may occur. Non-invasive diagnostic procedures are an unmet need. We aimed to identify a plasma microRNA (miRNA) signature for CRC detection. Plasma samples were obtained from subjects (n = 109) at different stages of colorectal carcinogenesis. The patients were stratified into a non-cancer (27 healthy volunteers, 17 patients with hyperplastic polyps, 24 with adenomas), and a cancer group (20 CRC and 21 metastatic CRC). miRNAs (381) were screened by TaqMan Low-Density Array. A classifier based on four differentially expressed miRNAs (miR-28-3p, let-7e-5p, miR-106a-5p, and miR-542-5p) was able to discriminate cancer versus non-cancer cases. The overexpression of these miRNAs was confirmed by RT-qPCR, and a cross-study validation step was implemented using eight data series retrieved from Gene Expression Omnibus (GEO). In addition, another external data validation using CRC surgical specimens from The Cancer Genome Atlas (TCGA) was carried out. The predictive model’s performance in the validation set was 76.5% accuracy, 59.4% sensitivity, and 86.8% specificity (area under the curve, AUC = 0.716). The employment of our model in the independent publicly available datasets confirmed a good discrimination performance in five of eight datasets (median AUC = 0.823). Applying this algorithm to the TCGA cohort, we found 99.5% accuracy, 99.7% sensitivity, and 90.9% specificity (AUC = 0.998) when the model was applied to solid colorectal tissues. Overall, we suggest a novel signature of four circulating miRNAs, i.e., miR-28-3p, let-7e-5p, miR-106a-5p, and miR-542-5p, as a predictive tool for the detection of CRC.

show abstract

“…Worldwide, colorectal cancer (CRC) is the third most prevalent malignant tumor in both men and women and is the third most common factor for tumor-related deaths (1). With the continuous progress of hospital diagnosis and treatment, the 5-year survival period of patients with CRC is extending (2). However, early diagnosis is difficult due to its occult onset.…”

Section: Introductionmentioning

confidence: 99%

Downregulating Long Non-coding RNAs CTBP1-AS2 Inhibits Colorectal Cancer Development by Modulating the miR-93-5p/TGF-β/SMAD2/3 Pathway

Jiang

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Background: Colorectal cancer (CRC), the most commonly diagnosed cancer in the world, has a high mortality rate. In recent decades, long non-coding RNAs (lncRNAs) have been proven to exert an important effect on CRC growth. However, the CTBP1-AS2 expression and function in CRC are largely unknown.Materials and Methods: The CTBP1-AS2 and miR-93-5p expression in CRC and para-cancerous tissues was detected by reverse transcription-PCR. The expression of CTBP1-AS2, miR-93-5p and the transforming growth factor-beta (TGF-β)/small mothers against decapentaplegic 2/3 (SMAD2/3) pathway was selectively regulated to study the correlation between CTBP1-AS2 expression and prognosis of patients with CRC. CRC cell proliferation, apoptosis, and invasion were measured in vivo and in vitro. In addition, bioinformatics was applied to explore the targeting relationship between CTBP1-AS2 and miR-93-5p. The targeting binding sites between CTBP1-AS2 and miR-93-5p, as well as between miR-93-5p and TGF-β, were verified by the dual-luciferase reporter assay and the RNA immunoprecipitation experiment.Results: Compared with normal para-cancerous tissues, CTBP1-AS2 was considerably overexpressed in CRC tissues and was closely associated with worse survival of patients with CRC. Functionally, gain and loss in experiments illustrated that CTBP1-AS2 accelerated CRC cell proliferation and invasion and inhibited cell apoptosis. Mechanistically, CTBP1-AS2 regulated the malignant phenotype of tumor cells through the TGF-β/SMAD2/3 pathway. Moreover, miR-93-5p, as an endogenous competitive RNA of CTBP1-AS2, attenuated the oncogenic effects mediated by CTBP1-AS2.Conclusion: CTBP1-AS2 promotes the TGF-β/SMAD2/3 pathway activation by inhibiting miR-93-5p, thereby accelerating CRC development.

show abstract

Early colorectal cancer: diagnosis, treatment and survivorship care

Cited by 138 publications

References 162 publications

Television Viewing Time and the Risk of Colorectal Cancer Mortality among Japanese Population: The JACC Study

Television Viewing Time and the Risk of Colorectal Cancer Mortality among Japanese Population: The JACC Study

Circulating let-7e-5p, miR-106a-5p, miR-28-3p, and miR-542-5p as a Promising microRNA Signature for the Detection of Colorectal Cancer

Downregulating Long Non-coding RNAs CTBP1-AS2 Inhibits Colorectal Cancer Development by Modulating the miR-93-5p/TGF-β/SMAD2/3 Pathway

Contact Info

Product

Resources

About